T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor

Journal of Virology

Volumn 84, Issue 8, 2010, Pages 4083-4088

  Full, Florian ^a   Lehner, Manfred ^a   Thonn, Veronika ^a   Goetz, Gabriel ^a   Scholz, Brigitte ^a   Kaufmann, Kerstin B ^a   Mach, Michael ^a   Abken, Hinrich ^b   Holter, Wolfgang ^a   Ensser, Armin ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; IMMUNOGLOBULIN RECEPTOR;

ADOPTIVE TRANSFER; ANTIVIRAL ACTIVITY; ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EFFECTOR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; CELL CULTURE; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PHYSIOLOGY; VIROLOGY;

CYTOMEGALOVIRUS;

CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 77950508107     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02117-09     Document Type: Article

References (36)

1. Birkholz, K., A. Hombach, C. Krug, S. Reuter, M. Kershaw, E. Kampgen, G. Schuler, H. Abken, N. Schaft, and J. Dorrie. 2009. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. Gene Ther. 16: 596-604.
2. Boeckh, M., and G. Boivin. 1998. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11: 533-554.
3. Boeckh, M., W. Leisenring, S. R. Riddell, R. A. Bowden, M. L. Huang, D. Myerson, T. Stevens-Ayers, M. E. Flowers, T. Cunningham, and L. Corey. 2003. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101: 407-414.
4. Boeckh, M., and P. Ljungman. 2009. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113: 5711-5719.
5. Boeckh, M., W. G. Nichols, G. Papanicolaou, R. Rubin, J. R. Wingard, and J. Zaia. 2003. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 9: 543-558.
6. Bohne, F., M. Chmielewski, G. Ebert, K. Wiegmann, T. Kurschner, A. Schulze, S. Urban, M. Kronke, H. Abken, and U. Protzer. 2008. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134: 239-247.
7. Boutolleau, D., C. Deback, C. Bressollette-Bodin, S. Varnous, N. Dhedin, B. Barrou, J. P. Vernant, I. Gandjbakhch, B. M. Imbert-Marcille, and H. Agut. 2009. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res. 81: 174-179.
8. del Val, M., K. Munch, M. J. Reddehase, and U. H. Koszinowski. 1989. Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell 58: 305-315.
9. Einsele, H., and H. Hebart. 2004. CMV-specific immunotherapy. Hum. Immunol. 65: 558-564.
10. Einsele, H., E. Roosnek, N. Rufer, C. Sinzger, S. Riegler, J. Loffler, U. Grigoleit, A. Moris, H. G. Rammensee, L. Kanz, A. Kleihauer, F. Frank, G. Jahn, and H. Hebart. 2002. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99: 3916-3922.
11. Eshhar, Z., T. Waks, G. Gross, and D. G. Schindler. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. U. S. A. 90: 720-724.
12. Hengel, H., and U. H. Koszinowski. 1997. Interference with antigen processing by viruses. Curr. Opin. Immunol. 9: 470-476.
13. Holtkamp, S., S. Kreiter, A. Selmi, P. Simon, M. Koslowski, C. Huber, O. Tureci, and U. Sahin. 2006. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108: 4009-4017.
14. Hombach, A., D. Koch, R. Sircar, C. Heuser, V. Diehl, W. Kruis, C. Pohl, and H. Abken. 1999. A chimeric receptor that selectively targets membranebound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 6: 300-304.
15. Kapp, M., S. M. Tan, H. Einsele, and G. Grigoleit. 2007. Adoptive immunotherapy of HCMV infection. Cytotherapy 9: 699-711.
16. Kershaw, M. H., M. W. Teng, M. J. Smyth, and P. K. Darcy. 2005. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 5: 928-940.
17. Kniess, N., M. Mach, J. Fay, and W. J. Britt. 1991. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J. Virol. 65: 138-146.
18. Kropff, B., and M. Mach. 1997. Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein. J. Gen. Virol. 78: 1999-2007.
19. pos T cell outgrowth. Virology 388: 15-20.
20. Masiero, S., V. C. Del, R. Gavioli, G. Mattiuzzo, M. G. Cusi, L. Micheli, F. Gennari, A. Siccardi, W. A. Marasco, G. Palu, and C. Parolin. 2005. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 12: 299-310.
21. Matthes-Martin, S., S. W. Aberle, C. Peters, W. Holter, T. Popow-Kraupp, U. Potschger, G. Fritsch, R. Ladenstein, A. Rosenmayer, K. Dieckmann, and H. Gadner. 1998. CMV-viraemia during allogenic bone marrow transplantation in paediatric patients: association with survival and graft-versus-host disease. Bone Marrow Transplant. 21 (Suppl. 2):S53-S56.
22. Patel, S. D., M. Moskalenko, T. Tian, D. Smith, R. McGuinness, L. Chen, G. A. Winslow, S. Kashmiri, J. Schlom, C. P. Stanners, M. H. Finer, and J. G. McArthur. 2000. T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. Cancer Gene Ther. 7: 1127-1134.
23. Peggs, K. S., S. Verfuerth, A. Pizzey, N. Khan, M. Guiver, P. A. Moss, and S. Mackinnon. 2003. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362: 1375-1377.
24. Powers, C., and K. Fruh. 2008. Rhesus CMV: an emerging animal model for human CMV. Med. Microbiol. Immunol. 197: 109-115.
25. Quinnan, G. V., Jr., N. Kirmani, A. H. Rook, J. F. Manischewitz, L. Jackson, G. Moreschi, G. W. Santos, R. Saral, and W. H. Burns. 1982. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307: 7-13.
26. Rapp, M., M. Messerle, B. Buhler, M. Tannheimer, G. M. Keil, and U. H. Koszinowski. 1992. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J. Virol. 66: 4399-4406.
27. Reddehase, M. J., C. O. Simon, C. K. Seckert, N. Lemmermann, and N. K. Grzimek. 2008. Murine model of cytomegalovirus latency and reactivation. Curr. Top. Microbiol. Immunol. 325: 315-331.
28. Reusser, P., H. Einsele, J. Lee, L. Volin, M. Rovira, D. Engelhard, J. Finke, C. Cordonnier, H. Link, and P. Ljungman. 2002. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99: 1159-1164.
29. Riddell, S. R., K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha, and P. D. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238-241.
30. Rivailler, P., A. Kaur, R. P. Johnson, and F. Wang. 2006. Genomic sequence of rhesus cytomegalovirus 180.92: insights into the coding potential of rhesus cytomegalovirus. J. Virol. 80: 4179-4182.
31. Rooney, C. M., C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13.
32. Scheinberg, P., J. J. Melenhorst, J. M. Brenchley, B. J. Hill, N. F. Hensel, P. K. Chattopadhyay, M. Roederer, L. J. Picker, D. A. Price, A. J. Barrett, and D. C. Douek. 2009. The transfer of adaptive immunity to cytomegalovirus (CMV) during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood 114: 5071-5080.
33. Smuda, C., E. Bogner, and K. Radsak. 1997. The human cytomegalovirus glycoprotein B gene (ORF UL55) is expressed early in the infectious cycle. J. Gen. Virol. 78: 1981-1992.
34. Sylwester, A. W., B. L. Mitchell, J. B. Edgar, C. Taormina, C. Pelte, F. Ruchti, P. R. Sleath, K. H. Grabstein, N. A. Hosken, F. Kern, J. A. Nelson, and L. J. Picker. 2005. Broadly targeted human cytomegalovirus-specific CD4 + and CD8 + T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202: 673-685.
35. Van Tendeloo, V., P. Ponsaerts, and Z. N. Berneman. 2007. mRNA-based gene transfer as a tool for gene and cell therapy. Curr. Opin. Mol. Ther. 9: 423-431.
36. Zhang, T., A. Barber, and C. L. Sentman. 2006. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66: 5927-5933.